SVB Wealth’s Quince Therapeutics QNCX Stock Holding History

SVB Wealth’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-75	Closed	-$20K	–	1083
2022 Q3	$20K	Buy	+75	New	+$28.6K	﹤0.01%	975

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SVB Wealth's QNCX Position: Q4 2022 in Review

SVB Wealth sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 75 shares — an estimated $20K sold.

SVB Wealth first reported a position in QNCX in Q3 2022 and held it in 1 quarter. The position peaked at $20K in Q3 2022. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

SVB Wealth reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
SVB Wealth sold 75 Quince Therapeutics shares in Q4 2022, an estimated $20K.
SVB Wealth first reported a position in Quince Therapeutics in Q3 2022 and held it in 1 quarter.
SVB Wealth's Quince Therapeutics position peaked at $20K in Q3 2022.
48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on SVB Wealth's 13F filing for Q4 2022, filed 10 Feb 2023.